Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
GlaxoSmithKline Protocol Summaries: Firategrast
American Medical Association fact sheet on ocrelizumab
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis.
Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica.
OBSERVATIONS ON ATTEMPTS TO PRODUCE ACUTE DISSEMINATED ENCEPHALOMYELITIS IN MONKEYS.
An Electrophoretic Study of the Protein Components in Cerebrospinal Fluid and their Relationship to the Serum Proteins.
Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.
Primary progressive multiple sclerosis-why we are failing.
CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
CellCept Drug Details
Neuroimmunology: Clostridium-reactive T cells are implicated in the pathogenesis of neuromyelitis optica.
The Relationships among MRI-Defined Spinal Cord Involvement, Brain Involvement, and Disability in Multiple Sclerosis.
BIIB033 single ascending dose study in healthy volunteer subjects
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study.
Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset.
Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis.
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
Newly onset sinus bradycardia in the context of multiple sclerosis relapse.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
The complex role of estrogens in inflammation.